UY25519A1 - Procedimiento para preparar antagonista del receptor de vitronectina - Google Patents

Procedimiento para preparar antagonista del receptor de vitronectina

Info

Publication number
UY25519A1
UY25519A1 UY25519A UY25519A UY25519A1 UY 25519 A1 UY25519 A1 UY 25519A1 UY 25519 A UY25519 A UY 25519A UY 25519 A UY25519 A UY 25519A UY 25519 A1 UY25519 A1 UY 25519A1
Authority
UY
Uruguay
Prior art keywords
phenyl
preparing
formula
vitronectin receptor
compounds
Prior art date
Application number
UY25519A
Other languages
English (en)
Inventor
H Miller William
G Gleason John
Dirk Heerding
M Samanen James
N Urinskas Irene
J Y Manley Peter
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of UY25519A1 publication Critical patent/UY25519A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

Procedimiento para preparar compuestos farmacéuticamente activos de fórmula general (Ia) representada en la figura 1, o una sal farmacéuticamente aceptable del mismo, donde: X e Y son independientemente CR`R`, NR`o S; R1 es alquil C0-C6-het, alquil-C0-C6-Ar, -H, -CN, o -S(O)kR9; R2 es un grupo de los representados en la figura 2, donde W es -(CHR9)a-U-(CHR9)b-; el procedimiento comprende hacer reaccionar un compuesto de fórmula (IV) con un compuesto de fórmula (V), ambas representadas en la figura 3, con todos los grupos funionales protegidos, siendo L1 OH u halo, y luego sepearar todos los grupos protectores, y opcionalmente formar una sal farmacéuticamente aceptable. Ejemplos de compuestos de fórmula general: Ácido (+)-3-fenil-4-[3-(piridin-2-il)amino-1-prpiloxifenil]butanoico; Ácido de (+)-3-fenil-4-[4-[2-[6-(metilamino)-piridin-2-il]-1-etoxi]fenil]butanoico; entre otros. Estos compuestos inhiben el receptor de vitronectina y son útiles para el tratamiento de inflamación, cáncer y transtornos cardiovasculares, tales como arteriosclerosis y restenosis, y enfermedades en las que la resorción ósea es un factor, tal como la osteoporosis.
UY25519A 1998-03-10 1999-05-19 Procedimiento para preparar antagonista del receptor de vitronectina UY25519A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7761098P 1998-03-10 1998-03-10
US9606398P 1998-08-11 1998-08-11
UY25421A UY25421A1 (es) 1998-03-10 1999-03-10 Antagonistas de receptor de vitronectina

Publications (1)

Publication Number Publication Date
UY25519A1 true UY25519A1 (es) 1999-12-13

Family

ID=26759473

Family Applications (2)

Application Number Title Priority Date Filing Date
UY25421A UY25421A1 (es) 1998-03-10 1999-03-10 Antagonistas de receptor de vitronectina
UY25519A UY25519A1 (es) 1998-03-10 1999-05-19 Procedimiento para preparar antagonista del receptor de vitronectina

Family Applications Before (1)

Application Number Title Priority Date Filing Date
UY25421A UY25421A1 (es) 1998-03-10 1999-03-10 Antagonistas de receptor de vitronectina

Country Status (24)

Country Link
EP (1) EP1061921A4 (es)
JP (1) JP2002506033A (es)
KR (1) KR20010041812A (es)
CN (1) CN1299282A (es)
AP (1) AP2000001898A0 (es)
AR (1) AR015241A1 (es)
AU (1) AU758498B2 (es)
BG (1) BG104824A (es)
BR (1) BR9908636A (es)
CA (1) CA2323208A1 (es)
CO (1) CO5080762A1 (es)
DZ (1) DZ2741A1 (es)
EA (1) EA200000921A1 (es)
HU (1) HUP0101143A3 (es)
ID (1) ID26223A (es)
IL (1) IL138245A0 (es)
NO (1) NO20004503L (es)
OA (1) OA12189A (es)
PE (1) PE20000323A1 (es)
PL (1) PL342881A1 (es)
SK (1) SK13292000A3 (es)
TR (1) TR200002625T2 (es)
UY (2) UY25421A1 (es)
WO (1) WO1999045927A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19939980A1 (de) 1999-08-24 2001-03-01 Merck Patent Gmbh Inhibitoren des Integrins alphavbeta¶3¶
DE19939981A1 (de) * 1999-08-24 2001-03-01 Merck Patent Gmbh Neue Inhibitoren des Integrins alphavß3
EG24179A (en) * 1999-09-07 2008-09-28 Smithkline Beecham Corp Vitronectin receptor antagonists
US6881736B1 (en) 1999-09-07 2005-04-19 Smithkline Beecham Corporation Vitronectin receptor antagonists
GB9930570D0 (en) * 1999-12-23 2000-02-16 Pfizer Ltd Therapy
US6448278B2 (en) 1999-12-23 2002-09-10 Pfizer Inc. Procollagen C-proteinase inhibitors
FR2808798A1 (fr) * 2000-05-09 2001-11-16 Hoechst Marion Roussel Inc Nouveaux derives antagonistes du recepteur de la vitronectine
PE20020665A1 (es) 2000-06-15 2002-08-14 Pharmacia Corp ACIDO CICLOALQUIL FENIL ALCANOICO COMO ANTAGONISTA DE INTEGRINAS OVß3
US6531494B1 (en) 2001-08-29 2003-03-11 Pharmacia Corporation Gem-substituted αvβ3 antagonists
US6645993B2 (en) 2001-03-30 2003-11-11 Warner-Lambert Company 3-heterocyclylpropanohydroxamic acid PCP inhibitors
US6716842B2 (en) 2002-04-05 2004-04-06 Warner-Lambert Company, Llc Antidiabetic agents
WO2005049589A2 (en) * 2003-10-14 2005-06-02 Cadila Healthcare Limited Heterocyclic compounds for the treatment of hyperlipidemia, diabetes, obesity and similar diseases
WO2005085241A1 (ja) * 2004-03-05 2005-09-15 Taisho Pharmaceutical Co., Ltd. チアゾール誘導体
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
JP2008536918A (ja) 2005-04-20 2008-09-11 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ フッ素置換ピリジンｎ−オキサイド系トロンビンモジュレーターおよび窒素含有ヘテロアリールのｎ−オキサイド化方法
WO2015030189A1 (ja) * 2013-08-29 2015-03-05 京都薬品工業株式会社 新規芳香族化合物およびその用途
HUE063437T2 (hu) 2013-09-24 2024-01-28 Fujifilm Corp Nitrogént tartalmazó vegyületet vagy sóját vagy fémkomplexét tartalmazó gyógyászati készítmény
KR20160147007A (ko) 2014-05-30 2016-12-21 화이자 인코포레이티드 선택적인 안드로겐 수용체 조절제로서의 카보니트릴 유도체
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1353897A (en) * 1995-12-29 1997-07-28 Smithkline Beecham Corporation Vitronectin receptor antagonists
WO1997024124A1 (en) * 1995-12-29 1997-07-10 Smithkline Beecham Corporation Vitronectin receptor antagonists

Also Published As

Publication number Publication date
PL342881A1 (en) 2001-07-16
EP1061921A4 (en) 2005-03-30
NO20004503L (no) 2000-10-10
EP1061921A1 (en) 2000-12-27
CO5080762A1 (es) 2001-09-25
KR20010041812A (ko) 2001-05-25
CN1299282A (zh) 2001-06-13
WO1999045927A1 (en) 1999-09-16
TR200002625T2 (tr) 2000-12-21
OA12189A (en) 2006-05-09
SK13292000A3 (sk) 2001-06-11
DZ2741A1 (fr) 2003-09-08
JP2002506033A (ja) 2002-02-26
CA2323208A1 (en) 1999-09-16
BR9908636A (pt) 2002-01-08
NO20004503D0 (no) 2000-09-08
IL138245A0 (en) 2001-10-31
PE20000323A1 (es) 2000-05-24
AP2000001898A0 (en) 2000-09-30
ID26223A (id) 2000-12-07
EA200000921A1 (ru) 2001-04-23
AU758498B2 (en) 2003-03-20
BG104824A (en) 2001-05-31
HUP0101143A2 (hu) 2001-08-28
AR015241A1 (es) 2001-04-18
AU2903399A (en) 1999-09-27
HUP0101143A3 (en) 2002-12-28
UY25421A1 (es) 2001-07-31

Similar Documents

Publication Publication Date Title
UY25519A1 (es) Procedimiento para preparar antagonista del receptor de vitronectina
NO20024217L (no) 1,5-benzotiazepiner og deres anvendelse som hypolidmidler
CY1110382T1 (el) Πυραζινο υποκατεστημενες αρυλοβενζοδιαζεπινες
AR029634A1 (es) Compuestos derivados heterociclicos utiles como agentes anticancerosos, composicion farmaceutica y procedimiento de tratamiento
KR950005817A (ko) 5원환을 갖는 벤조-융합된 헤테로사이클릭 화합물, 이의 제조방법, 약제로서의 이의 용도, 진단제로서의 이의 용도 및 이를 함유하는 약제
NO20050016L (no) Difenylazetidinonderivater for behandling av forstyrrelser i lipid metabolismen
RU94044677A (ru) Трехзамещенные фенильные производные, способ получения, фармацевтическая композиция
WO2002026712A3 (en) Quaternary amines and related inhibitors of factor xa
ES2158778B1 (es) Compuestos de sales de paroxetina, su preparacion y uso, y composiciones farmaceuticas que los contienen.
DK1029853T3 (da) Heteroaromatiske bicykliske derivativer, der er egnede som anticancermidler
DOP2001000170A (es) Derivados de tiofeno utiles como agentes anticancesoros
HK1080856A1 (en) Compounds having selective inhibiting effect at gsk3
NO992524L (no) Konsenserte bicykliske pyrimidin-derivater
GB9213623D0 (en) Therapeutic agents
PE20020721A1 (es) Derivados de quinuclidina como agentes antimuscarinicos m3
WO2001056989A3 (en) Inhibitors of factor xa
FI943142A0 (fi) Amidi- ja ureajohdannaiset, joilla on veren korkeita kolesteroliarvoja vastustava vaikutus, niiden valmistus ja terapeuttiset käytöt
RU94045149A (ru) Средство ингибирования легочных гипертонических заболеваний
EA012980B1 (ru) Замещённые фенокси- и фенилтиопроизводные для лечения пролиферативных нарушений
ES2100222T3 (es) Derivados del acido aminoalcansulfonico y compuestos farmaceuticos a utilizar para prevenir o tratar afecciones cardiacas.
PA8426801A1 (es) Composiciones farmaceuticas para el tratamiento de la rinitis.
PT97395A (pt) Processo para a preparacao de 2,9-di-substituidas-4h-pirido{1,2-a}-pirimidin-4-onas e de composicoes farmaceuticas que os contem
RU94037246A (ru) Применение 2-фенил-3-ароилбензотиофенов для ингибирования разрушения хряща
WO2001057021A3 (en) 2-[1H]-QUINOLONE AND 2-[1H]-QUINOXALONE INHIBITORS OF FACTOR Xa
AR054707A1 (es) Derivados de octahidropirrolo 3,4-c pirrol, un procedimiento para su preparacion, una composicion farmaceutica y uso del compuesto para la fabricacion de un medicamento

Legal Events

Date Code Title Description
DESI Application deemed to be withdrawn

Effective date: 20071105